A century past the discovery of insulin: global progress and challenges for type 1 diabetes among children and adolescents in low-income and middle-income countries.

Type 1 diabetes is on the rise globally; however, the burden of mortality remains disproportionate in low-income and middle-income countries (LMICs). As 2021 marks 100 years since the discovery of insulin, we revisit progress, global burden of type 1 diabetes trends, and understanding of the pathogenesis and management practices related to the disease. Despite much progress, inequities in access and availability of insulin formulations persist and are reflected in differences in survival and morbidity patterns related to the disease. Some of these inequities have also been exacerbated by health-system challenges during the COVID-19 pandemic. There is a clear opportunity to improve access to insulin and related essential technologies for improved management of type 1 diabetes in LMICs, especially as a part of universal health coverage. These improvements will require concerted action and investments in human resources, community engagement, and education for the timely diagnosis and management of type 1 diabetes, as well as adequate health-care financing. Further research in LMICs, especially those in Africa, is needed to improve our understanding of the burden, risk factors, and implementation strategies for managing type 1 diabetes.

Preventing and controlling noncommunicable diseases in the Caribbean

Noncommunicable diseases (NCDs) in the Caribbean represent not only a major health problem, but also a serious economic challenge. NCDs cause the death of some 16 000 persons prior to age 70 annually, making an obvious impact on economic productivity. The goal is to avoid 5 000 of those deaths per year by 2030 and to reduce the upward cost spiral.

Las dimensiones económicas de las enfermedades no transmisibles en América Latina y el Caribe / Economic Dimensions of Non-communicable Diseases in Latin America and the Caribbean

[Prefacio]. Las dimensiones económicas de las enfermedades no transmisibles (ENT) en América Latina y el Caribe (ALC), obra complementaria de Prioridades para el control de enfermedades (DPC3 por sus siglas en inglés) , explora el impacto y la relación entre las ENT y el desarrollo y crecimiento económico en los países de ALC. En los artículos que la component se examina la compleja interacción entre las ENT, el gasto sanitario y las inversiones económicas en las áreas de salud, pobreza e inequidades, utilizando para ello la información y los datos de investigación más recientes relativos a la región de ALC. Existen pruebas categóricas de que las ENT constituyen un problema de gran importancia cuya frecuencia va en aumento en los países de ingresos bajos y de ingresos medianos, y de que consumen proporciones cada vez mayors de los presupuestos destinados a la atención de salud. Las ENT no son simplemente la consecuencia indirecta del aumento de los ingresos y de la reducción paulatina de las enfermedades infecciosas, sino que también figuran entre las principales causas de discapacidad y mala salud y son la causa principal de muerte prevenible y prematura en las Américas. Las ENT generan cuantiosos gastos de bolsillo en salud tanto en los individuos como en las familias, así como enormes desembolsos en salud en los presupuestos nacionales. Durante los últimos 20 años, muchos países de ALC han tenido un crecimiento económico sin precedentes; y a pesar de la reciente crisis económica mundial, los indicadores económicos y de salud han mejorado en términos generales, especialmente en el plano nacional. Sin embargo, las ENT siguen poniendo en riesgo el crecimiento económico y el potencial de desarrollo de muchas naciones, sobre todo de aquellas de ingresos bajos y medianos que enfrentan un aumento más marcado de la carga de ENT como resultado del rápido crecimiento y envejecimiento de sus poblaciones. Estas enfermedades propician la inequidad; menoscaban los logros económicos de las personas, las comunidades y las sociedades, y obstaculizan el desarrollo de manera sostensible. Es imprescindible conocer más a fondo las repercusiones económicas de las ENT y mitigar sus consecuencias nocivas para las sociedades [...] En la presente obra también se aprovechan las evidencias previas y se evalúan las investigaciones empíricas más recientes con la finalidad de influir en la formulación de políticas, la preparación de programas y la asignación de recursos en torno a las ENT en los planos regional y nacional. Esta publicación también recomienda medidas específicas y hace un llamado a la participación de toda la sociedad en el manejo de las ENT como un problema económico urgente y un obstáculo al desarrollo. Con estos objetivos en mente se redactó Las dimensiones económicas de las enfermedades no transmisibles en América Latina y el Caribe, fruto de la labor de asesores técnicos de la OPS y de muchos otros expertos en el tema. La obra está dirigida a un auditorio variado que comprende desde académicos y profesionales de la salud hasta formuladores de políticas y directores de programas, así como medios de comunicación, legisladores y público en general. En la preparación de este libro, la OPS colaboró con el Banco Mundial, el Instituto Nacional de Salud Pública de México y la Disease Control Priorities Network (Red de prioridades en la lucha contra las enfermedades), del Departamento de Salud Global de la Universidad de Washington. Asimismo, la OPS contrató a destacados investigadores de toda la región ALC. Cada artículo se escribió por separado, en función de los conocimientos y las experiencia de los distintos autores.

Economic Dimensions of Non-Communicable Disease in Latin America and the Caribbean. Disease Control Priorities. 3. ed. Companion Volume

[Foreword]. Economic Dimensions of Noncommunicable Diseases in Latin America and the Caribbean is a companion volume to Disease Control Priorities, Third Edition (DCP3). This volume explores the relationship between and the impact of noncommunicable diseases (NCDs) on development and economic growth in the countries of Latin America and the Caribbean (LAC). This collection of manuscripts examines the complex interplay among NCDs, health expenditures and financial investments in health, poverty, and inequities, using up-to-date information and evidence from the LAC region. There is compelling proof that NCDs are a major and growing problem for low- and middle-income countries, and that they consume increasingly greater proportions of health care budgets. NCDs are not simply a byproduct of higher incomes and declining infectious disease rates, but are also a major cause of disability and ill health and the leading cause of preventable and premature mortality in the Americas. NCDs are responsible for significant out-of-pocket health expenditures for individuals and families, as well as substantial health outlays in national budgets [...] Economic Dimensions of Noncommunicable Diseases in Latin America and the Caribbean recognizes the relationship between NCDs and sociodemographic trends in the LAC region. These include unprecedented rates of urbanization, globalization, rapid population aging, and inadequate health system responses to these changes. This volume provides health planners and decision makers with relevant information about how NCDs contribute to economic development and makes a case for greater investments in the prevention and control of chronic conditions. This book also builds on previous evidence and assesses new empirical work, with the goal of influencing NCD policies, program design, and resource allocation at the regional and country level. The volume also recommends specific, concrete actions and calls for an all-of-society approach to address NCDs as both an urgent economic concern and a development issue. With these objectives in mind, Economic Dimensions of Noncommunicable Diseases in Latin America and the Caribbean has been written by PAHO technical advisors and a range of other, specially selected experts, for an audience that ranges from academics and health professionals to policy makers and program managers, as well as the media, lawmakers, and the general public.

[Global health 2035: a world converging within a generation]. / Salud global 2035: un mundo convergiendo en el lapso de una generación.

Prompted by the 20th anniversary of the 1993 World Development Report, a Lancet Commission revisited the case for investment in health and developed a new investment framework to achieve dramatic health gains by 2035. The Commission's report has four key messages, each accompanied by opportunities for action by national governments of low-income and middle-income countries and by the international community. First, there is an enormous economic payoff from investing in health. The impressive returns make a strong case for both increased domestic financing of health and for allocating a higher proportion of official development assistance to development of health. Second, modeling by the Commission found that a "grand convergence" in health is achievable by 2035-that is, a reduction in infectious, maternal, and child mortality down to universally low levels. Convergence would require aggressive scale up of existing and new health tools, and it could mostly be financed from the expected economic growth of low- and middle-income countries. The international community can best support convergence by funding the development and delivery of new health technologies and by curbing antibiotic resistance. Third, fiscal policies -such as taxation of tobacco and alcohol- are a powerful and underused lever that governments can use to curb non-communicable diseases and injuries while also raising revenue for health. International action on NCDs and injuries should focus on providing technical assistance on fiscal policies, regional cooperation on tobacco, and funding policy and implementation research on scaling-up of interventions to tackle these conditions. Fourth, progressive universalism, a pathway to universal health coverage (UHC) that includes the poor from the outset, is an efficient way to achieve health and financial risk protection. For national governments, progressive universalism would yield high health gains per dollar spent and poor people would gain the most in terms of health and financial protection. The international community can best support countries to implement progressive UHC by financing policy and implementation research, such as on the mechanics of designing and implementing evolution of the benefits package as the resource envelope for public finance grows.

Salud global 2035: un mundo convergiendo en el lapso de una generación / Global health 2035: a world converging within a generation

Con motivo del 20º aniversario del Informe sobre el Desarrollo Mundial 1993, una Comisión de la revista The Lancet reconsideró el argumento a favor de la inversión en salud y desarrolló un nuevo marco de inversión para lograr mejoras dramáticas en materia de salud para el año 2035. El informe de la Comisión contiene cuatro mensajes clave, cada uno acompañado de oportunidades para los gobiernos nacionales de países de ingresos bajos y medios y para la comunidad internacional. En primer lugar, invertir en salud acarrea enormes rendimientos económicos. Las impresionantes ganancias son un fuerte argumento a favor de un aumento en el financiamiento nacional de la salud y de asignar una mayor proporción de la asistencia oficial al desarrollo de la salud. En segundo lugar, en el modelo creado por la Comisión se encontró que es posible lograr para el año 2035 una "gran convergencia" en salud, consistente en la reducción de las tasas de mortalidad materna, infantil y por infecciones a niveles universalmente bajos. Tal convergencia requeriría la ampliación de las herramientas de salud existentes y un incremento agresivo de nuevas herramientas, y podría ser financiada en su mayor parte con recursos derivados del crecimiento económico esperado de los países de ingresos bajos y medios. La mejor manera en que la comunidad internacional puede apoyar la convergencia es financiando el desarrollo y suministro de nuevas tecnologías de salud, y frenando la resistencia a los antibióticos. En tercer lugar, las políticas fiscales -tales como los impuestos al tabaco y al alcohol- son una palanca poderosa y subutilizada que los gobiernos pueden emplear para detener el avance de las enfermedades no transmisibles (ENT) y las lesiones, a la vez que elevan los ingresos públicos para la salud. La acción internacional sobre las ENT y lesiones debería enfocarse en proporcionar asistencia técnica sobre políticas fiscales, en cooperación regional para el combate al tabaquismo y en financiar investigación sobre políticas e implementación para ampliar las intervenciones que enfrenten estos problemas. En cuarto lugar, la universalización progresiva -una vía hacia la cobertura universal de salud (CUS) que incluya desde el comienzo a los pobres- es una manera eficiente de lograr la protección a la salud contra riesgos financieros. Para los gobiernos nacionales, la universalización progresiva produciría elevadas ganancias en salud por cada dólar que se gaste en ésta, y los pobres serían quienes más ganarían en términos tanto de salud como de protección financiera. La mejor manera en que la comunidad internacional puede brindar apoyo a los países para implementar una CUS progresiva es financiando la investigación sobre políticas e implementación, por ejemplo, sobre la mecánica del diseño e instrumentación de la evolución del paquete de beneficios conforme crezca el presupuesto para las finanzas públicas.

Prompted by the 20th anniversary of the 1993 World Development Report, a Lancet Commission revisited the case for investment in health and developed a new investment framework to achieve dramatic health gains by 2035. The Commission's report has four key messages, each accompanied by opportunities for action by national governments of low-income and middle-income countries and by the international community. First, there is an enormous economic payoff from investing in health. The impressive returns make a strong case for both increased domestic financing of health and for allocating a higher proportion of official development assistance to development of health. Second, modeling by the Commission found that a "grand convergence" in health is achievable by 2035-that is, a reduction in infectious, maternal, and child mortality down to universally low levels. Convergence would require aggressive scale up of existing and new health tools, and it could mostly be financed from the expected economic growth of low- and middle-income countries. The international community can best support convergence by funding the development and delivery of new health technologies and by curbing antibiotic resistance. Third, fiscal policies -such as taxation of tobacco and alcohol- are a powerful and underused lever that governments can use to curb non-communicable diseases and injuries while also raising revenue for health. International action on NCDs and injuries should focus on providing technical assistance on fiscal policies, regional cooperation on tobacco, and funding policy and implementation research on scaling-up of interventions to tackle these conditions. Fourth, progressive universalism, a pathway to universal health coverage (UHC) that includes the poor from the outset, is an efficient way to achieve health and financial risk protection. For national governments, progressive universalism would yield high health gains per dollar spent and poor people would gain the most in terms of health and financial protection. The international community can best support countries to implement progressive UHC by financing policy and implementation research, such as on the mechanics of designing and implementing evolution of the benefits package as the resource envelope for public finance grows.

Lessons and Leadership in Health Comment on "Improving the World's Health through the Post-2015 Development Agenda: Perspectives from Rwanda".

This paper comments on the principles that informed Rwanda's successful efforts to adapt its health system to population needs, and more specifically to reduce health inequities. The point is made that these may be universally applicable for countries as they deal with the challenges of post-2015 health agenda.

From the Earth Summit to Rio+20: integration of health and sustainable development.

In 2012, world leaders will meet at the Rio+20 conference to advance sustainable development--20 years after the Earth Summit that resulted in agreement on important principles but insufficient action. Many of the development goals have not been achieved partly because social (including health), economic, and environmental priorities have not been addressed in an integrated manner. Adverse trends have been reported in many key environmental indicators that have worsened since the Earth Summit. Substantial economic growth has occurred in many regions but nevertheless has not benefited many populations of low income and those that have been marginalised, and has resulted in growing inequities. Variable progress in health has been made, and inequities are persistent. Improved health contributes to development and is underpinned by ecosystem stability and equitable economic progress. Implementation of policies that both improve health and promote sustainable development is urgently needed.

Global health: the twenty-first century global health priority agenda.

Growth in global health interest in the past 20 years has been overwhelming and many universities throughout the world have created departments or institutes of global health. The essence of global health has to be promoting health equity globally. The global health agenda must embrace design of mixed health systems, involving both private and public components to address the emerging threat of noncommunicable diseases and existing communicable diseases as well as to reduce health inequity. The priority agenda for the twenty-first century is challenging but the improvements of the past give hope that the barriers to improving global health are surmountable.

Priority actions for the non-communicable disease crisis.

The UN High-Level Meeting on Non-Communicable Diseases (NCDs) in September, 2011, is an unprecedented opportunity to create a sustained global movement against premature death and preventable morbidity and disability from NCDs, mainly heart disease, stroke, cancer, diabetes, and chronic respiratory disease. The increasing global crisis in NCDs is a barrier to development goals including poverty reduction, health equity, economic stability, and human security. The Lancet NCD Action Group and the NCD Alliance propose five overarching priority actions for the response to the crisis--leadership, prevention, treatment, international cooperation, and monitoring and accountability--and the delivery of five priority interventions--tobacco control, salt reduction, improved diets and physical activity, reduction in hazardous alcohol intake, and essential drugs and technologies. The priority interventions were chosen for their health effects, cost-effectiveness, low costs of implementation, and political and financial feasibility. The most urgent and immediate priority is tobacco control. We propose as a goal for 2040, a world essentially free from tobacco where less than 5% of people use tobacco. Implementation of the priority interventions, at an estimated global commitment of about US$9 billion per year, will bring enormous benefits to social and economic development and to the health sector. If widely adopted, these interventions will achieve the global goal of reducing NCD death rates by 2% per year, averting tens of millions of premature deaths in this decade.

Expansion of cancer care and control in countries of low and middle income: a call to action.

Substantial inequalities exist in cancer survival rates across countries. In addition to prevention of new cancers by reduction of risk factors, strategies are needed to close the gap between developed and developing countries in cancer survival and the effects of the disease on human suffering. We challenge the public health community's assumption that cancers will remain untreated in poor countries, and note the analogy to similarly unfounded arguments from more than a decade ago against provision of HIV treatment. In resource-constrained countries without specialised services, experience has shown that much can be done to prevent and treat cancer by deployment of primary and secondary caregivers, use of off-patent drugs, and application of regional and global mechanisms for financing and procurement. Furthermore, several middle-income countries have included cancer treatment in national health insurance coverage with a focus on people living in poverty. These strategies can reduce costs, increase access to health services, and strengthen health systems to meet the challenge of cancer and other diseases. In 2009, we formed the Global Task Force on Expanded Access to Cancer Care and Control in Developing Countries, which is composed of leaders from the global health and cancer care communities, and is dedicated to proposal, implementation, and evaluation of strategies to advance this agenda.

Advancement of global health: key messages from the Disease Control Priorities Project.

The Disease Control Priorities Project (DCPP), a joint project of the Fogarty International Center of the US National Institutes of Health, the WHO, and The World Bank, was launched in 2001 to identify policy changes and intervention strategies for the health problems of low-income and middle-income countries. Nearly 500 experts worldwide compiled and reviewed the scientific research on a broad range of diseases and conditions, the results of which are published this week. A major product of DCPP, Disease Control Priorities in Developing Countries, 2nd edition (DCP2), focuses on the assessment of the cost-effectiveness of health-improving strategies (or interventions) for the conditions responsible for the greatest burden of disease. DCP2 also examines crosscutting issues crucial to the delivery of quality health services, including the organisation, financial support, and capacity of health systems. Here, we summarise the key messages of the project.

Combating tropical infectious diseases: report of the Disease Control Priorities in Developing Countries Project.

Infectious diseases are responsible for >25% of the global disease toll. The new Disease Control Priorities in Developing Countries Project (DCPP) aims to decrease the burden of these diseases by producing science-based analyses from demographic, epidemiologic, disease intervention, and economic evidence for the purpose of defining disease priorities and implementing control measures. The DCPP recently reviewed selected tropical infectious diseases, examined successful control experiences, and defined unsettled patient treatment, prevention, and research issues. Disease elimination programs against American trypanosomiasis (Chagas disease), onchocerciasis, lymphatic filariasis, leprosy, trachoma, and measles are succeeding. Dengue, leishmaniasis, African trypanosomiasis, malaria, diarrheal diseases, helminthic infections, and tuberculosis have reemerged because of inadequate interventions and control strategies and the breakdown of health delivery systems. Application of technologies must be cost-effective and intensified research is essential if these and other scourges are to be controlled or eliminated in the 21st century.